Eugen Stermetz
Director of Finance/CFO bij SWISSCOM AG
Vermogen: 107 133 $ op 31-03-2024
Profiel
Momenteel is Eugen Stermetz Chief Financial Officer bij Swisscom AG. In zijn vorige loopbaan was hij Financieel Directeur bij FIBREX Medical, Inc., Financieel Directeur bij F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH, Financieel Directeur van igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH, Financieel Directeur bij SVOX AG en Management Consultant bij Boston Consulting Group Service GmbH. Eugen Stermetz behaalde een doctoraat aan de Universiteit van Wenen en een bachelor aan de Universiteit van St. Gallen.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
SWISSCOM AG
0.00% | 31-12-2022 | 175 ( 0.00% ) | 107 133 $ | 31-03-2024 |
Actieve functies van Eugen Stermetz
Bedrijven | Functie | Begin |
---|---|---|
SWISSCOM AG | Director of Finance/CFO | 01-03-2021 |
Swisscom (Schweiz) AG
Swisscom (Schweiz) AG Major TelecommunicationsCommunications Swisscom (Schweiz) AG engages in the provision of telecommunications, broadcasting, and information technology services. It also specializes in the marketing of products for computer systems, including the design, development, and licensing of software. The company was founded on December 9, 1997 and is headquartered in Bern, Switzerland. | Director/Board Member | - |
Pensionskasse comPlan | Director/Board Member | - |
Fastweb SpA
Fastweb SpA Major TelecommunicationsCommunications Fastweb SpA engages in the provision of solutions for internet connectivity. The firm offers a wide range of voice and data services, fixed communication, and mobile to households and businesses. It also constructs fiber optic network infrastructure and adopts internet protocol for voice, data, and video transmission. The company was founded by Silvio Scaglia in September 1999 and is headquartered in Milan, Italy. | Director/Board Member | - |
Eerdere bekende functies van Eugen Stermetz
Bedrijven | Functie | Einde |
---|---|---|
SVOX AG
SVOX AG Packaged SoftwareTechnology Services SVOX AG develops speech, voice and language output solutions and related equipment. The company was founded by Volker P. Jantzen, Alexander E. Fries and Bettina Hein in April 2000 and is headquartered in Zurich, Switzerland. | Director of Finance/CFO | 01-01-2011 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Director of Finance/CFO | 01-01-2008 |
Igeneon AG | Director of Finance/CFO | 01-01-2005 |
Boston Consulting Group Service GmbH
Boston Consulting Group Service GmbH Miscellaneous Commercial ServicesCommercial Services Part of BCG Holding Group SCS, Boston Consulting Group Service GmbH is a German company that provides management consulting services. The private company is based in Munich, Germany. | Corporate Officer/Principal | - |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Director of Finance/CFO | - |
Opleiding van Eugen Stermetz
University of Vienna | Doctorate Degree |
University of St. Gallen | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SWISSCOM AG | Communications |
Bedrijven in privébezit | 9 |
---|---|
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Commercial Services |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Health Technology |
Fastweb SpA
Fastweb SpA Major TelecommunicationsCommunications Fastweb SpA engages in the provision of solutions for internet connectivity. The firm offers a wide range of voice and data services, fixed communication, and mobile to households and businesses. It also constructs fiber optic network infrastructure and adopts internet protocol for voice, data, and video transmission. The company was founded by Silvio Scaglia in September 1999 and is headquartered in Milan, Italy. | Communications |
SVOX AG
SVOX AG Packaged SoftwareTechnology Services SVOX AG develops speech, voice and language output solutions and related equipment. The company was founded by Volker P. Jantzen, Alexander E. Fries and Bettina Hein in April 2000 and is headquartered in Zurich, Switzerland. | Technology Services |
Swisscom (Schweiz) AG
Swisscom (Schweiz) AG Major TelecommunicationsCommunications Swisscom (Schweiz) AG engages in the provision of telecommunications, broadcasting, and information technology services. It also specializes in the marketing of products for computer systems, including the design, development, and licensing of software. The company was founded on December 9, 1997 and is headquartered in Bern, Switzerland. | Communications |
Igeneon AG | |
Pensionskasse comPlan | |
Boston Consulting Group Service GmbH
Boston Consulting Group Service GmbH Miscellaneous Commercial ServicesCommercial Services Part of BCG Holding Group SCS, Boston Consulting Group Service GmbH is a German company that provides management consulting services. The private company is based in Munich, Germany. | Commercial Services |